NCT04421677View on ClinicalTrials.gov

Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

January 20, 2022

Study Completion Date

January 20, 2022

Conditions
Inclusion Body MyositisSporadic Inclusion Body Myositis
Interventions
DRUG

Phenylbutyrate Oral Tablet

Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT04421677 - Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis | Biotech Hunter | Biotech Hunter